BDX
Neutral signalScored 2026-08-16 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Becton, Dickinson and Company
- Nom
- Becton, Dickinson and Company
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NYSE
- Capitalisation
- $54.3B
- Employés
- 72,000
- PDG
- Thomas E. Polen Jr.
- Site web
- https://www.bd.com
- Marché
- ABTBAXBLFSEMBCICUIMDT
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 4 152 titres (~768 120,00 $ US)
- Insiders
- Polen Thomas E Jr
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,265,855
Avg sell (VWAP, 90d window) $183.30 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$824,967 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-13
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-28 | Feld Michael | Sell · S · 10b5-1 | 76 | $183.70 | $13,961 | Form 4 |
| 2026-08-26 | Feld Michael | Sell · S · 10b5-1 | 165 | $188.49 | $31,101 | Form 4 |
| 2026-08-13 | Polen Thomas E Jr | Sell · S · 10b5-1 | 4,152 | $185.00 | $768,120 | Form 4 |
| 2026-08-11 | Goette Roland | Sell · S | 2,438 | $180.84 | $440,888 | Form 4 |
| 2026-07-27 | Feld Michael | Sell · S · 10b5-1 | 75 | $157.13 | $11,785 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-21 | Thomas H. Kean | Sale | $1,001 - $15,000 |
| 2026-03-17 | Kevin Hern | Sale | $15,001 - $50,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-06-24 | Lisa McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-13 | Thomas H. Kean | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale | $1,001 - $15,000 |
| 2025-03-05 | Jefferson Shreve | Sale | $15,001 - $50,000 |
| 2024-09-11 | William R. Keating | Sale | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-05-24 | Thomas H. Kean | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-03-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-11 | Thomas H. Kean | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-25 | Zoe Lofgren | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-04-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-09 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-04-22 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-02-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-10-28 | Kim Schrier | Sale (Full) | $1,001 - $15,000 |
| 2021-06-22 | John Curtis | Sale (Full) | $1,001 - $15,000 |
| 2021-05-12 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2021-04-09 | Sara Jacobs | Sale (Full) | $15,001 - $50,000 |
| 2020-11-30 | Michael McCaul | Sale (Full) | $50,001 - $100,000 |
| 2020-11-30 | Michael McCaul | Sale (Full) | $50,001 - $100,000 |
| 2020-11-27 | Michael McCaul | Sale (Full) | $50,001 - $100,000 |
| 2020-11-27 | Michael McCaul | Sale (Full) | $50,001 - $100,000 |
| 2020-11-19 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2020-09-22 | Francis Rooney | Purchase | $1,001 - $15,000 |
| 2020-09-10 | Francis Rooney | Purchase | $1,001 - $15,000 |
| 2020-08-26 | Francis Rooney | Purchase | $1,001 - $15,000 |
| 2020-08-25 | David B. McKinley | Sale (Full) | $15,001 - $50,000 |
| 2020-08-20 | David B. McKinley | Sale (Full) | $1,001 - $15,000 |
| 2020-05-22 | Robert J. Wittman | Sale (Full) | $1,001 - $15,000 |
| 2020-05-19 | K. Michael Conaway | Sale (Full) | $15,001 - $50,000 |
| 2020-04-30 | David B. McKinley | Purchase | $1,001 - $15,000 |
| 2020-04-30 | David B. McKinley | Purchase | $1,001 - $15,000 |
| 2020-04-09 | Kevin Hern | Purchase | $1,001 - $15,000 |
| 2020-03-27 | John Curtis | Purchase | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-10-30 | Mikie Sherrill | Sale (Full) | $50,001 - $100,000 |
| 2019-07-09 | Elizabeth Fletcher | Sale (Full) | $1,001 - $15,000 |
| 2019-06-12 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2019-04-18 | K. Michael Conaway | Purchase | $1,001 - $15,000 |
| 2019-02-26 | Elizabeth Fletcher | Sale (Full) | $1,001 - $15,000 |
| 2019-02-05 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2018-11-21 | K. Michael Conaway | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-16 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.11 · operating margin 12%
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 45.4% | 45.2% | 42.2% | 44.9% | 45.1% | |
| Ebit Margin | 11.4% | 12.6% | 10.9% | 11.6% | 11.3% | |
| Ebitda Margin | 22.7% | 23.9% | 22.7% | 23.4% | 23.0% | |
| Operating Profit Margin | 11.8% | 11.9% | 10.9% | 12.1% | 11.8% | |
| Pretax Profit Margin | 8.6% | 9.9% | 8.6% | 9.4% | 8.8% | |
| Continuous Operations Profit Margin | 7.7% | 8.4% | 7.9% | 8.7% | 8.4% | |
| Net Profit Margin | 7.7% | 8.4% | 7.7% | 9.4% | 10.9% | |
| Bottom Line Profit Margin | 7.7% | 8.4% | 7.4% | 9.0% | 10.5% | |
| Current Ratio | 1.113 | 1.169 | 1.306 | 1.042 | 1.334 | |
| Quick Ratio | 0.645 | 0.740 | 0.814 | 0.629 | 0.920 | |
| Solvency Ratio | 0.138 | 0.127 | 0.140 | 0.145 | 0.143 | |
| Cash Ratio | 0.102 | 0.207 | 0.213 | 0.148 | 0.361 | |
| Price To Earnings Ratio | 25.197 | 32.235 | 40.895 | 29.541 | 27.246 | |
| Price To Earnings Growth Ratio | -37.039 | 1.761 | -2.526 | -2.065 | 0.180 | |
| Forward Price To Earnings Growth Ratio | -37.039 | 1.761 | -2.526 | -2.065 | 0.180 | |
| Price To Earnings Diluted Ratio | 25.240 | 32.345 | 41.144 | 29.793 | 27.524 | |
| Price To Earnings Diluted Growth Ratio | -49.302 | 1.737 | -2.574 | -2.104 | 0.180 | |
| Price To Book Ratio | 1.661 | 2.121 | 2.256 | 1.975 | 2.304 | |
| Price To Sales Ratio | 1.931 | 2.722 | 3.004 | 2.646 | 2.851 | |
| Price To Free Cash Flow Ratio | 15.796 | 17.878 | 27.511 | 30.077 | 15.967 | |
| Price To Operating Cash Flow Ratio | 12.296 | 14.461 | 19.467 | 18.962 | 11.737 | |
| Debt To Assets Ratio | 0.347 | 0.377 | 0.319 | 0.320 | 0.342 | |
| Debt To Equity Ratio | 0.755 | 0.834 | 0.652 | 0.670 | 0.778 | |
| Debt To Capital Ratio | 0.430 | 0.455 | 0.395 | 0.401 | 0.438 | |
| Long Term Debt To Capital Ratio | 0.410 | 0.418 | 0.370 | 0.361 | 0.424 | |
| Financial Leverage Ratio | 2.179 | 2.213 | 2.046 | 2.094 | 2.276 | |
| Working Capital Turnover Ratio | 17.799 | 11.378 | 16.382 | 14.847 | 7.158 | |
| Operating Cash Flow Ratio | 0.413 | 0.424 | 0.450 | 0.337 | 0.701 | |
| Operating Cash Flow Sales Ratio | 0.157 | 0.188 | 0.154 | 0.140 | 0.243 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.778 | 0.809 | 0.708 | 0.630 | 0.735 | |
| Debt Service Coverage Ratio | 2.187 | 1.591 | 2.497 | 1.581 | 3.930 | |
| Interest Coverage Ratio | 4.206 | 4.540 | 4.670 | 5.734 | 4.797 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.199 | 1.643 | 2.376 | 1.146 | 7.423 | |
| Operating Cash Flow Coverage Ratio | 0.179 | 0.176 | 0.178 | 0.155 | 0.252 | |
| Capital Expenditure Coverage Ratio | 4.513 | 5.239 | 3.420 | 2.706 | 3.775 | |
| Dividend Paid And Capex Coverage Ratio | 1.754 | 2.081 | 1.504 | 1.281 | 2.039 | |
| Dividend Payout Ratio | 0.713 | 0.645 | 0.751 | 0.608 | 0.501 | |
| Enterprise Value Multiple | 12.206 | 15.491 | 16.718 | 14.902 | 16.073 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 45.4% | ▲0.2% | ▲0.9% |
| Ebit Margin | 11.4% | ▼-1.1% | ▼-0.1% |
| Ebitda Margin | 22.7% | ▼-1.2% | ▼-0.4% |
| Operating Profit Margin | 11.8% | ▼-0.1% | ▲0.1% |
| Pretax Profit Margin | 8.6% | ▼-1.3% | ▼-0.5% |
| Continuous Operations Profit Margin | 7.7% | ▼-0.8% | ▼-0.5% |
| Net Profit Margin | 7.7% | ▼-0.8% | ▼-1.1% |
| Bottom Line Profit Margin | 7.7% | ▼-0.8% | ▼-0.9% |
| Current Ratio | 1.113 | ▼-0.056 | ▼-0.080 |
| Quick Ratio | 0.645 | ▼-0.095 | ▼-0.105 |
| Solvency Ratio | 0.138 | ▲0.011 | ▼-0.000 |
| Cash Ratio | 0.102 | ▼-0.105 | ▼-0.104 |
| Price To Earnings Ratio | 25.197 | ▼-7.038 | ▼-5.826 |
| Price To Earnings Growth Ratio | -37.039 | ▼-38.800 | ▼-29.101 |
| Forward Price To Earnings Growth Ratio | -37.039 | ▼-38.800 | ▼-29.101 |
| Price To Earnings Diluted Ratio | 25.240 | ▼-7.105 | ▼-5.969 |
| Price To Earnings Diluted Growth Ratio | -49.302 | ▼-51.039 | ▼-38.890 |
| Price To Book Ratio | 1.661 | ▼-0.460 | ▼-0.402 |
| Price To Sales Ratio | 1.931 | ▼-0.791 | ▼-0.700 |
| Price To Free Cash Flow Ratio | 15.796 | ▼-2.082 | ▼-5.650 |
| Price To Operating Cash Flow Ratio | 12.296 | ▼-2.165 | ▼-3.089 |
| Debt To Assets Ratio | 0.347 | ▼-0.030 | ▲0.006 |
| Debt To Equity Ratio | 0.755 | ▼-0.078 | ▲0.017 |
| Debt To Capital Ratio | 0.430 | ▼-0.024 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.410 | ▼-0.009 | ▲0.013 |
| Financial Leverage Ratio | 2.179 | ▼-0.034 | ▲0.018 |
| Working Capital Turnover Ratio | 17.799 | ▲6.421 | ▲4.286 |
| Operating Cash Flow Ratio | 0.413 | ▼-0.011 | ▼-0.052 |
| Operating Cash Flow Sales Ratio | 0.157 | ▼-0.031 | ▼-0.019 |
| Free Cash Flow Operating Cash Flow Ratio | 0.778 | ▼-0.030 | ▲0.046 |
| Debt Service Coverage Ratio | 2.187 | ▲0.596 | ▼-0.170 |
| Interest Coverage Ratio | 4.205 | ▼-0.334 | ▼-0.584 |
| Short Term Operating Cash Flow Coverage Ratio | 2.199 | ▲0.556 | ▼-0.759 |
| Operating Cash Flow Coverage Ratio | 0.179 | ▲0.003 | ▼-0.009 |
| Capital Expenditure Coverage Ratio | 4.513 | ▼-0.726 | ▲0.583 |
| Dividend Paid And Capex Coverage Ratio | 1.754 | ▼-0.328 | ▲0.022 |
| Dividend Payout Ratio | 0.713 | ▲0.068 | ▲0.069 |
| Enterprise Value Multiple | 12.206 | ▼-3.285 | ▼-2.872 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $42.17B | $54.92B | $58.19B | $49.93B | $54.54B | |
| Enterprise value | $60.50B | $74.65B | $73.59B | $65.72B | $70.57B | |
| EV / Sales | 2.77x | 3.70x | 3.80x | 3.48x | 3.69x | |
| EV / Op. cash flow | 17.64x | 19.66x | 24.62x | 24.96x | 15.19x | |
| EV / Free cash flow | 22.66x | 24.30x | 34.80x | 39.59x | 20.66x | |
| EV / EBITDA | 12.21x | 15.49x | 16.72x | 14.90x | 16.07x | |
| Net debt / EBITDA | 3.70x | 4.09x | 3.50x | 3.58x | 3.65x | |
| Current ratio | 1.11x | 1.17x | 1.31x | 1.04x | 1.33x | |
| Income quality | 2.04x | 2.23x | 1.95x | 1.48x | 2.22x | |
| Graham number | $108 | $109 | $103 | $112 | $115 | |
| Graham net-net | -$87 | -$86 | -$77 | -$82 | -$85 | |
| Tax burden | 89.2% | 85.0% | 89.3% | 99.8% | 123.6% | |
| Interest burden | 75.4% | 79.2% | 78.6% | 81.8% | 78.3% | |
| Working capital | $942.0M | $1.51B | $2.04B | $330.0M | $2.21B | |
| Invested capital | $43.96B | $45.72B | $44.06B | $43.27B | $44.88B | |
| Return on assets | 3.0% | 3.0% | 2.8% | 3.4% | 3.9% | |
| Operating ROA | 4.6% | 4.4% | 4.0% | 4.3% | 4.2% | |
| Return on tangible assets | 8.7% | 8.6% | 8.6% | 11.1% | 12.2% | |
| Return on equity | 6.6% | 6.6% | 5.8% | 7.0% | 8.8% | |
| Return on invested capital | 4.7% | 4.0% | 4.1% | 4.4% | 4.5% | |
| Return on capital employed | 5.5% | 5.0% | 4.6% | 5.1% | 4.8% | |
| Earnings yield | 4.0% | 3.1% | 2.6% | 3.6% | 3.8% | |
| Free cash flow yield | 6.3% | 5.6% | 3.6% | 3.3% | 6.3% | |
| Capex / Op. cash flow | 22.2% | 19.1% | 29.2% | 37.0% | 26.5% | |
| Capex / Depreciation | 30.9% | 31.7% | 38.2% | 43.7% | 54.2% | |
| Capex / Sales | 3.5% | 3.6% | 4.5% | 5.2% | 6.4% | |
| SG&A / Sales | 24.2% | 24.1% | 24.4% | 25.0% | 24.7% | |
| R&D / Sales | 5.8% | 5.9% | 6.4% | 6.7% | 6.7% | |
| Stock comp / Sales | 1.2% | 1.2% | 1.3% | 1.2% | 1.2% | |
| Intangibles / Total assets | 65.1% | 65.3% | 67.2% | 69.8% | 68.1% | |
| Days sales outstanding | 50d | 55d | 48d | 42d | 45d | |
| Days payables outstanding | 60d | 63d | 53d | 60d | 60d | |
| Operating cycle | 169d | 182d | 154d | 156d | 140d | |
| Cash conversion cycle | 109d | 119d | 101d | 96d | 80d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-17 BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
- 2026-08-13 Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
- 2026-08-13 Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
- 2026-08-12 BDX DCF Analysis: Intrinsic Value $141 vs Price $181 On August 12, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance recently, with a year-to-
- 2026-08-12 BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
- 2026-08-11 First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value On June 30, 2026, First Eagle Investment (Trades, Portfolio) executed a significant add transaction for Becton Dickinson and Co (NYSE: BDX), increasing the firm''s
- 2026-08-10 We Said These 4 Dividend Aristocrats Could Soar. Here''s How They Did, Plus 3 New Picks. About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
- 2026-08-07 Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures Revenue: $5 billion, up 4.4% on an FX-neutral basis.Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year.Adjusted Gross Margin: 54.3%,
- 2026-08-07 Becton, Dickinson and Company Q3 Earnings Call Highlights Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company''s expectations.
- 2026-08-06 BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.